As insulin prices continue to rise, many patients find themselves making painful sacrifices, often choosing between their medication and basic necessities like food and rent. This critical situation has sparked a series of legal challenges targeting the practices of insulin manufacturers and pharmacy benefit managers (PBMs). Accusations against these companies include violating antitrust laws, engaging in racketeering activities under the RICO Act, and unjust enrichment. Plaintiffs in these cases are demanding substantial compensation for the exorbitant amounts paid due to artificially inflated prices, as well as punitive damages intended to deter such unethical behavior in the future.